Regen BioPharma, Inc. Announces ucVax: Universal Donor Cancer Cellular Immunotherapy
Company Initiates Preclinical Development of Cells Capable of Seeking and Destroying Cancer
PR Newswire Regen BioPharma Inc.
4 hours ago
SAN DIEGO, May 19, 2016 /PRNewswire/ --
Regen BioPharma, Inc. (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today initiation of a preclinical development program aimed at creating the first cord blood based cancer immunotherapeutic product leveraging its NR2F6 immunological checkpoint. In a provisional patent application, Regen described a generation of cord blood derived killer cells whose anti-cancer activity was potentiated by gene silencing. The product in development will be a "universal donor" cellular immunotherapy, which can be shipped frozen to the site of use and does not involve complex cellular manipulations by the treating institution.
"Developing a universal donor immunotherapy will substantially reduce costs of clinical implementation and allow for wide access to treatment including at institutions that do not possess cellular processing abilities. To our knowledge, "universal donor" cellular immunotherapies have not been developed to date. We believe ucVax will possess both therapeutic and commercial advantages as compared to other immunotherapies," said David Koos, Ph.D., Chairman and CEO of Regen BioPharma.
Currently cancer cellular immunotherapies involve extraction of patient blood cells, manipulation of the cells outside of the body, followed by subsequent re-infusion. The disadvantage of these approaches include the costs of generating personalized cellular products, as well as the need for each institution to possess cell manipulation facilities.
"We are pleased to announce expansion of our NR2F6 gene-silencing technologies to the area of universal donor cellular products. ucVax leverages experimental data gathered from our ongoing work in the development of dCellVax (IND # 16200) and tCellVax (IND #16928), both of which are personalized cellular immunotherapies," said Harry Lander Ph.D., President and Chief Scientific Officer of Regen BioPharma. "By using cord blood cells as the starting population for generation of ucVax, we overcome the problem of immune rejection by the patient receiving the therapy, thus potentially allowing the therapy to be used by everyone in need."
Not the news we want RIGHT NOW, but good news nonetheless. Of course, spinners will spin.
BMSN
AI
